Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Fried

Showing results (81-90 of 166) with videos related to

Pageof 17
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2016
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal functionVarun Saxena, Farrukh M Koraishy, Meghan E Sise, et al.
Hepatology (Baltimore, Md.)|September 30, 2008
High relapse rate seen at week 72 for patients treated with R1626 combination therapyPaul Pockros, David Nelson, Eliot Godofsky, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 20, 2021
Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019Elizabeth C Verna, Charles Landis, Robert S Brown, et al.
Hepatology (Baltimore, Md.)|January 15, 2013
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to careChristopher E McGowan, Ali Monis, Bruce R Bacon, et al.
Hepatology (Baltimore, Md.)|October 12, 2007
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseJordan J Feld, Santosh Nanda, Ying Huang, et al.
Alimentary Pharmacology & Therapeutics|July 16, 2025
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASHBrent A Neuschwander-Tetri, Heather L Morris, Andrea R Mospan, et al.
Gut|October 10, 2015
Hepatitis C virus treatment in the real world: optimising treatment and access to therapiesFabien Zoulim, T Jake Liang, Alexander L Gerbes, et al.
Hepatitis Research and Treatment|October 25, 2012
Hepatitis C virus: a critical appraisal of new approaches to therapyDavid R Nelson, Donald M Jensen, Mark S Sulkowski, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 8, 2015
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaXavier Forns, Fred Poordad, Marcos Pedrosa, et al.
Open Forum Infectious Diseases|May 30, 2019
Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and CanadaDavid R McGivern, Hsing-Hua S Lin, Junyao Wang, et al.
Pageof 17

Showing results (81-90 of 166) with videos related to

Sort By:
Pageof 17
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2016
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal functionVarun Saxena, Farrukh M Koraishy, Meghan E Sise, et al.
Hepatology (Baltimore, Md.)|September 30, 2008
High relapse rate seen at week 72 for patients treated with R1626 combination therapyPaul Pockros, David Nelson, Eliot Godofsky, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 20, 2021
Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019Elizabeth C Verna, Charles Landis, Robert S Brown, et al.
Hepatology (Baltimore, Md.)|January 15, 2013
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to careChristopher E McGowan, Ali Monis, Bruce R Bacon, et al.
Hepatology (Baltimore, Md.)|October 12, 2007
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseJordan J Feld, Santosh Nanda, Ying Huang, et al.
Alimentary Pharmacology & Therapeutics|July 16, 2025
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASHBrent A Neuschwander-Tetri, Heather L Morris, Andrea R Mospan, et al.
Gut|October 10, 2015
Hepatitis C virus treatment in the real world: optimising treatment and access to therapiesFabien Zoulim, T Jake Liang, Alexander L Gerbes, et al.
Hepatitis Research and Treatment|October 25, 2012
Hepatitis C virus: a critical appraisal of new approaches to therapyDavid R Nelson, Donald M Jensen, Mark S Sulkowski, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 8, 2015
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaXavier Forns, Fred Poordad, Marcos Pedrosa, et al.
Open Forum Infectious Diseases|May 30, 2019
Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and CanadaDavid R McGivern, Hsing-Hua S Lin, Junyao Wang, et al.
Pageof 17